Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 May 7;10(5):800-7.
doi: 10.2215/CJN.10221014. Epub 2015 Apr 17.

The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial

Jürgen Floege  1 , Yumi Kubo  2 , Anna Floege  3 , Glenn M Chertow  4 , Patrick S Parfrey  5
Affiliations
Randomized Controlled Trial

The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial

Jürgen Floege et al. Clin J Am Soc Nephrol. .

Abstract

Background and objectives: Uncontrolled secondary hyperparathyroidism (sHPT) in patients with ESRD is a risk factor for calcific uremic arteriolopathy (CUA; calciphylaxis).

Design, setting, participants, & measurements: Adverse event reports collected during the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events trial were used to determine the frequency of CUA in patients receiving hemodialysis who had moderate to severe sHPT, as well as the effects of cinacalcet versus placebo. CUA events were collected while patients were receiving the study drug.

Results: Among the 3861 trial patients who received at least one dose of the study drug, 18 patients randomly assigned to placebo and six assigned to cinacalcet developed CUA (unadjusted relative hazard, 0.31; 95% confidence interval [95% CI], 0.13 to 0.79; P=0.014). Corresponding cumulative event rates (95% CI) at year 4 were 0.011% (0.006% to 0.018%) and 0.005% (0.002% to 0.010%). By multivariable analysis, other factors associated with CUA included female sex, higher body mass index, higher diastolic BP, and history of dyslipidemia or parathyroidectomy. Median (10%, 90% percentile) plasma parathyroid hormone concentrations proximal to the report of CUA were 796 (225, 2093) pg/ml and 410 (71, 4957) pg/ml in patients randomly assigned to placebo and cinacalcet, respectively. Active use of vitamin K antagonists was recorded in 11 of 24 patients with CUA, nine randomly assigned to placebo, and two to cinacalcet, in contrast to 5%-7% at any one time point in patients in whom CUA was not reported.

Conclusion: Cinacalcet appeared to reduce the incidence of CUA in hemodialysis recipients who have moderate to severe sHPT.

Trial registration: ClinicalTrials.gov NCT00345839.

Keywords: calcium receptor; dialysis; hyperparathyroidism; hyperphosphatemia; mineral metabolism.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cumulative incidence plot of time to calcific uremic arteriolopathy adverse event (safety analysis set).
See this image and copyright information in PMC

Comment in

References

    1. Brandenburg VM, Sinha S, Specht P, Ketteler M: Calcific uraemic arteriolopathy: A rare disease with a potentially high impact on chronic kidney disease-mineral and bone disorder. Pediatr Nephrol 29: 2289–2298, 2014 - PubMed
    1. Coates T, Kirkland GS, Dymock RB, Murphy BF, Brealey JK, Mathew TH, Disney AP: Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 32: 384–391, 1998 - PubMed
    1. Fine A, Zacharias J: Calciphylaxis is usually non-ulcerating: Risk factors, outcome and therapy. Kidney Int 61: 2210–2217, 2002 - PubMed
    1. Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, Stehman-Breen CO: Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 60: 324–332, 2001 - PubMed
    1. Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR: Calciphylaxis: Natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56: 569–579, 2007 - PubMed

Publication types

MeSH terms

Associated data